Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marker Therapeutics, Inc.

1.70
-0.2200-11.46%
Post-market: 1.730.0297+1.75%19:59 EDT
Volume:1.78M
Turnover:3.14M
Market Cap:19.24M
PE:-1.27
High:1.89
Open:1.80
Low:1.63
Close:1.92
Loading ...

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance Cgmp Manufacturing of Mt-601, a Multi-Antigen Recognizing T Cell Therapy for Patients With Lymphoma

THOMSON REUTERS
·
17 Jun

Marker Therapeutics Inc. Announces Collaboration with Cellipont Bioservices for cGMP Manufacturing of Promising MT-601 T Cell Therapy for Lymphoma

Reuters
·
17 Jun

Marker Therapeutics Inc. Concluded Annual Stockholders Meeting

Reuters
·
10 Jun

Marker Therapeutics Inc. Unveils Presentation on MAR-T Cell Platform and Lead Product MT-601 for Tumor Treatment

Reuters
·
05 Jun

Marker Therapeutics Inc. Releases Document on Lymphodepletion Enhancing MAR-T Cell Response in Lymphoma

Reuters
·
20 May

BRIEF-Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Reuters
·
20 May

Marker Therapeutics reports evidence from Phase 1 APOLLO study

TIPRANKS
·
20 May

Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients With Lymphoma

THOMSON REUTERS
·
20 May

Canaccord Genuity Sticks to Its Buy Rating for Marker Therapeutics (MRKR)

TIPRANKS
·
19 May

Marker Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Marker Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
09 May

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

GlobeNewswire
·
01 Apr

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity

TIPRANKS
·
01 Apr

Marker Therapeutics Price Target Maintained With a $12.50/Share by WBB Securities

Dow Jones
·
01 Apr

Marker Therapeutics FY Net Income USD -10.7 Million

THOMSON REUTERS
·
31 Mar

Press Release: Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Dow Jones
·
31 Mar

Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
21 Mar

Marker Therapeutics up 8% After Canaccord Genuity Initiates Coverage With "Buy" Rating

THOMSON REUTERS
·
06 Mar

Canaccord Genuity Initiates Marker Therapeutics at Buy With $8 Price Target

MT Newswires Live
·
05 Mar

Marker Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
05 Mar